FATTY ACIDS FOR PREVENTION OF COMPLICATIONS AFTER MYOCARDIAL INFARCTION. COST-UTILITY ANALYSIS

Use of highly concentrated ethyl esters of polyunsaturated fatty acids after myocardial infarction (MI) and in patients with heart failure was associated with lower mortality. ^e goal of this analysis was to perform cost-utility analysis of the use of highly concentrated ethyl esters of polyunsaturated fatty acids after MI (with help of a Markov model) and to find whether its use in some group of patients led to decrease in budget costs. As a result, we have shown that use of highly concentrated ethyl esters of polyunsaturated fatty acids after MI leads to increase in quality-adjusted life expectancy on 0.5 QALY, with incremental cost-effectiveness ratio of 105 thousand rubles per QALY, and net monetary benefit of 780.5 thousand rubles. In the patient subpopulation that receives highly concentrated ethyl esters of polyunsaturated fatty acids for arrhythmia prevention after coronary artery bypass the estimated decrease of budget cost varies between 6 and 50% depending on denominator used.

инфаркт миокарда, смерть от сердечно-сосудистых заболеваний, полиненасыщенные жирные кислоты, анализ стоимость-полезность, число сохраненных лет жизни с поправкой на ее качество (QALY), myocardial infarction, cardiovascular mortality, polyunsaturated fatty acids, cost-utility analysis, quality-adjusted life years (QALY), myocardial infarction, cardiovascular mortality, polyunsaturated fatty acids, cost-utility analysis, quality-adjusted life years (QALY)

1. GISSI. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999; 354 (9177):447-455.

2. Rizos E. C., Ntzani E. E., Bika E. et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308 (10):1024-1033.

3. Rizos E. C., Elisaf M. S. Does Supplementation with Omega-3 PUFAs Add to the Prevention of Cardiovascular Disease? Curr Cardiol Rep 2017;19 (6):47-55.

4. Tavazzi L., Maggioni A. P., Marchioli R. et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372 (9645):1223-1230.

5. Yokoyama M., Origasa H., Matsuzaki M. et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369 (9567):1090-1098.

6. Galan P., Kesse-Guyot E., Czernichow S. et al. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. BMJ 2010;341: c6273.

7. Kromhout D., Giltay E.J., Geleijnse J. M. et al. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363 (21):2015-2026.

8. Rauch B., Schiele R., Schneider S. et al. OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 2010;122 (21):2152-2159.

9. ORIGIN Trial Investigators, Bosch J., Gerstein H. C. et al. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. New Engl J Med 2012;367 (4):309-318.

10. Roncaglioni M. C., Tombesi M., Avanzini F. et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med 2013;368 (19):1800-1808.

11. Christou G. A., Christou K. A., Korantzopoulos P. et al. The Current Role of Omega-3 Fatty Acids in the Management of Atrial Fibrillation. Int J Mol Sci 2015;16 (9):22870-22887.

12. Ramsden C. E., Hibbeln J. R., Majchrzak S. F., Davis J. M. n-6 fatty acid-specific and mixed polyunsaturate dietary interventions have different effects on CHD risk: a meta-analysis of randomised controlled trials. Br J Nutr 2010;104 (11):1586-1600.

13. Sin'kova M. N., Pepelyaeva T. V., Isakov L. K., Tarasov N. I., Teplyakov A. T. Long-term effects of omega-3 polyunsaturated fatty acids on the course of ischemic heart disease in patients after ST-elevation myocardial infarction at the background of multiple-vessel lesion coronary atherosclerosis. Cardiovascular Therapy and Prevention 2014;13 (6): 32-37.

14. Lamotte M., Annemans L., Kawalec P., Zoellner Y. A multi-country health economic evaluation of highly concentrated N-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. Pharmacoeconomics 2006;24 (8):783-795.

15. Rudakova A. V. Cost-effectiveness of omega-3 polyunsaturated fatty acids in the treatment of cardiovascular diseases. Clinical pharmacology and therapy 2011;20 (3):75-79.

16. Weinblatt E., Goldberg J. D., Ruberman W. et al. Mortality after first myocardial infarction. Search for a secular trend. JAMA 1982;247 (11):1576-1581.

17. Johansson S., Rosengren A., Young K., Jennings E. Mortality and morbidity trends after the first year in survivors of acute myocardial infarction: a systematic review. BMC Cardiovasc Disord 2017;17 (1):53.

18. Smolina K., Wright F. L., Rayner M., Goldacre M.J. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circ Cardiovasc Qual Outcomes 2012;5 (4):532-540.

19. Zhang Y. F., Gao H. F., Hou A. J., Zhou Y. H. Effect of omega-3 fatty acid supplementation on cancer incidence, non-vascular death, and total mortality: a meta-analysis of randomized controlled trials. BMC Public Health 2014;14:204.

20. Costanzo S., di Niro V., Di Castelnuovo A. et al. Prevention of postoperative atrial fibrillation in open heart surgery patients by preoperative supplementation of n-3 polyunsaturated fatty acids: an updated meta-analysis. J Thorac Cardiovasc Surg 2013;146 (4):906-911.

21. Calo L., Bianconi L., Colivicchi F. et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol 2005;45 (10):1723-1728.

22. Permpanich A., Kulsomboon V., Udol K. Cost-effectiveness analysis of highly concentrated n-3 polyunsaturated fatty acids in secondary prevention after myocardial infarction. Asian Biomed 2015;9 (1):21-30.

23. Filipovic-Pierucci A., Zarca K., Durand-Zaleski I. Markov models for health economic evaluation: The r package heemod. ArXiv e-prints 2017 R package version 0.9.1. 1702.03252.

24. Yagudina R. I., Kulikov A. Yu., Nguen T. Place of threshold willing-ness-to-pay of Russia among those of other European countries and CIS countries. PharmacoEconomics 2011; 4 (1):7-12

25. Kolbin A. S., Maximkina Е. А., Kurylev А. А. Cost of additional effectiveness of antineoplastic drugs (according to restrictive lists). Remedium 2016; 11:56-60

26. Fox K. A., Fitzgerald G., Puymirat E. et al. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated G^ACE risk score. BMJ Open 2014;4 (2):e004425.

27. Villareal R. P., Hariharan R., Liu B. C. et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004;43 (5):742-748.

28. Mathew J. P., Parks R., Savino J. S. et al. Atrial fibrillation following coronary artery bypass graft surgery: predictors, outcomes, and resource utilization. MultiCenter Study of Perioperative Ischemia Research Group. JAMA 1996;276 (4):300-306.